Kailera Therapeutics (NASDAQ:KLRA) Reaches New 1-Year Low – What’s Next?

Kailera Therapeutics, Inc. (NASDAQ:KLRA)’s share price hit a new 52-week low during trading on Monday. The company traded as low as $10.20 and last traded at $10.20, with a volume of 51759 shares changing hands. The stock had previously closed at $10.39.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings began coverage on Kailera Therapeutics in a research report on Friday, August 14th. They set a “sell (d)” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Kailera Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $42.75.

Kailera Therapeutics Price Performance

The company has a 50-day moving average price of $15.41. The firm has a market capitalization of $1.40 billion and a P/E ratio of -0.00.

Kailera Therapeutics (NASDAQ:KLRA) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.35). As a group, analysts anticipate that Kailera Therapeutics, Inc. will post -3.89 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Tidal Investments LLC bought a new stake in Kailera Therapeutics during the second quarter worth $309,000. Squarepoint Ops LLC bought a new position in Kailera Therapeutics during the 2nd quarter valued at $993,000. State Street Corp purchased a new position in Kailera Therapeutics during the 2nd quarter worth $19,126,000. Frazier Life Sciences Management L.P. purchased a new position in Kailera Therapeutics during the 2nd quarter worth $24,233,000. Finally, Wellington Management Group LLP purchased a new stake in shares of Kailera Therapeutics in the second quarter valued at about $64,308,000.

About Kailera Therapeutics

Kailera Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for obesity and other chronic metabolic diseases. The company’s research is centered on therapies designed to address weight management and related health conditions.

Kailera’s pipeline includes ecnoglutide, an investigational, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for potential use in obesity and metabolic disorders. The company continues to advance clinical development and assess additional opportunities in the metabolic disease sector.

Kailera Therapeutics is focused primarily on research and development activities, with its programs intended for potential commercialization in international markets subject to clinical, regulatory and other approvals.